[{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Institut Pasteur Korea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Launches COVID-19 Program in Collaboration With Institut Pasteur Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncology Venture\u2019s Novel PARP Inhibitor Stenoparib Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncology Venture"},{"orgOrder":0,"company":"AdaptVac","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$4.6 million","newsHeadline":"Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"AdaptVac"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics to Test Activity of Stenoparib, as a Potential Therapy for New Highly Infectious Strain B.1.1.7 of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib\u2019s Antiviral Activity Against New Variants of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity\u2019s Stenoparib, Shows Additional Pre-Clinical Antiviral Activity Against New Variants of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Viroclinics Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics\u2019 Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Evaxion Biotech"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"ExpreS2ion Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion and ExpreS\u00b2ion Initiate Research Collaboration On A Novel Cytomegalovirus (CMV) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Evaxion Biotech"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Presents Promising Results on EVX-B1, an AI-designed Vaccine Against Staphylococcus Aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Evaxion Biotech"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Evaxion Biotech"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Evaxion Biotech"},{"orgOrder":0,"company":"Synklino","sponsor":"The Danish Growth Fund","pharmaFlowCategory":"D","amount":"$31.8 million","upfrontCash":"Undisclosed","newsHeadline":"Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for The Treatment of Cytomegalovirus (CMV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Synklino"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The collaboration aims at developing a novel, prophylactic, mRNA vaccine, EVX-B2, based on Evaxion’s EDEN™ platform, a proprietary AI platform capable of rapidly identifying those antigens that will trigger a highly protective immune response, to discover gonorrhea targets.
EVX-B3, an AI-designed vaccine using both its EDEN™ and RAVEN™ AI platforms to identify protective antigens capable of eliciting both a humoral (antibody) and cellular response to the pathogen.
EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective against S. aureus disease in preclinical animal models.
Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the EVX-V1 (CMV vaccine candidate) under a potential development and commercialization agreement.
In preclinical studies, the vaccine candidate EVX-B2 (multivalent gonorrhea vaccine) has demonstrated protection against infection, holding great promise for future development and the patients in need.
Synklino will advance its drug candidate SYN002 for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials and generate safety and efficacy data establishing a solid foundation.
The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.
Currently, the delta variant (lineage B.1.617.2) has become the dominant strain of SARS-CoV-2, and near-term tests of stenoparib against this variant are being initiated by Allarity.
The current and planned in-vitro studies, focusing on SARS-CoV-2 lineage B.1.1.7 and B.1.351, follow previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2 published in the peer-review journal mBio.
Based on the previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2, Allarity Therapeutics will now test the similar ability of stenoparib to block the infection and replication of SARS-CoV-2 lineage B.1.1.7.